Comparison of immune profiles between hepatocellular carcinoma subtypes

Xuemin Pan; Ping Lin; Fangyoumin Feng; Jia Li; Yuan-Yuan Li; Wentao Dai; Bo Hu; Xin-Rong Yang; Jia Fan; Hong Li; Yixue Li

doi:10.1007/s41048-019-00102-w

Volume 6 Issue 1

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2020 > 6(1): 19-32

Xuemin Pan, Ping Lin, Fangyoumin Feng, Jia Li, Yuan-Yuan Li, Wentao Dai, Bo Hu, Xin-Rong Yang, Jia Fan, Hong Li, Yixue Li. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports, 2020, 6(1): 19-32. doi: 10.1007/s41048-019-00102-w

Citation:

Xuemin Pan, Ping Lin, Fangyoumin Feng, Jia Li, Yuan-Yuan Li, Wentao Dai, Bo Hu, Xin-Rong Yang, Jia Fan, Hong Li, Yixue Li. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports, 2020, 6(1): 19-32. doi: 10.1007/s41048-019-00102-w

Citation:

Xuemin Pan, Ping Lin, Fangyoumin Feng, Jia Li, Yuan-Yuan Li, Wentao Dai, Bo Hu, Xin-Rong Yang, Jia Fan, Hong Li, Yixue Li. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports, 2020, 6(1): 19-32. doi: 10.1007/s41048-019-00102-w

PDF (3646 KB)

Comparison of immune profiles between hepatocellular carcinoma subtypes

doi: 10.1007/s41048-019-00102-w

Xuemin Pan¹,
Ping Lin^2,8,
Fangyoumin Feng^2,7,8,
Jia Li^2,7,8,
Yuan-Yuan Li^4,5,
Wentao Dai^4,5,
Bo Hu⁶,
Xin-Rong Yang⁶,
Jia Fan⁶,
Hong Li²,
Yixue Li^1,2,3,4,5

1 School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
2 Bio-Med Big Data Center, Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China
3 Collaborative Innovation Center of Genetics and Development, Fudan University, Shanghai 200433, China
4 Shanghai Center for Bioinformation Technology, Shanghai Academy of Science & Technology, Shanghai 201203, China
5 Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai 201203, China
6 Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China
7 School of Life Science and Techonology, ShanghaiTech University, Shanghai 211210, China
8 University of the Chinese Academy of Sciences, Beijing 100049, China

Funds: Hong Li, Yixue Li

Received Date: 15 March 2019
Rev Recd Date: 19 June 2019
Publish Date: 29 February 2020

Abstract

Abstract

Immunotherapy, especially immune checkpoint inhibitors, is becoming a promising treatment for hepatocellular carcinoma (HCC). However, the response rate remains limited due to the heterogeneity of HCC samples. Molecular subtypes of HCC vary in genomic background, clinical features, and prognosis. This study aims to compare the immune profiles between HCC subtypes and find subtype-specific immune characteristics that might contribute to the prognosis and potential of immunotherapy. The immune profiles consist of immune-related genes, cytolytic activity, immune pathways, and tumorinfiltrating lymphocytes. HCC-c1 samples showed an overall higher activation level of immune genes and pathways, and this pattern was consistent in validation sets. We associated the difference in immune profiles with the activation level of cancer hallmarks and genomic mutations. There was a negative correlation between most of the metabolism pathway and immune-related pathways in HCC samples. CTNNB1/WNT signaling pathway mutation, one of the common mutations in HCC, appears to be associated with the expression of immune genes as well. These results reveal the difference of immune profiles between HCC subtypes and possible reasons and influence, which may also deepen our understanding of the carcinogenesis process.
- Hepatocellular carcinoma,
- Immune,
- Tumor-infiltrating lymphocytes,
- Metabolism,
- CTNNB1 mutation

FullText(HTML)

References(58)

References

Allison KE, Coomber BL, Bridle BW (2017) Metabolic reprogramming in the tumour microenvironment:a hallmark shared by cancer cells and T lymphocytes. Immunology 152:175-184

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK (2017) IFNgamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930-2940

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO:archive for functional genomics data sets-update. Nucleic Acids Res. 41(D1):D991-D995

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424

Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki J-P, Ollivier-Hourmand I, Kudo M, Cheng A-L, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, Investigators RESORCE (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (Lond, Engl) 389:56-66

Carambia A, Herkel J (2018) Dietary and metabolic modulators of hepatic immunity. Semin Immunopathol 40:175-188

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18:248-262

Davis S, Meltzer PS (2007) GEOquery:a bridge between the gene expression omnibus (GEO) and bioconductor. Bioinformatics 23:1846-1847

Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z, Nan L, Li X, Wang Z, Huo X, Han L, Wu Z, Wu E, Ma Q (2015) Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget 6:1490-1506

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim T-Y, Choo S-P, Trojan J, Welling THR, Meyer T, Kang Y-K, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (Lond, Engl) 389:2492-2502

El-Serag HB (2011) Current concepts hepatocellular carcinoma. N Engl J Med 365:1118-1127

Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E, Baldelli F (2010) Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 10:579-595

Fiorucci S, Biagioli M, Zampella A, Distrutti E (2018) Bile acids activated receptors regulate innate immunity. Front Immunol 9:1853

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet(Lond, Engl) 391:1301-1314

Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717-734

Gaborit N, Lindzen M, Yarden Y (2016) Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother 12:576-592

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1

Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, Santos A, Lopez-Bigas N (2013) IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods 10:1081-1082

Guha P, Reha J, Katz SC (2017) Immunosuppression in liver tumors:opening the portal to effective immunotherapy. Cancer Gene Ther 24:114-120

Guo X, Xiong L, Zou L, Zhao J (2012) Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 18:635-640

Hänzelmann S, Castelo R, Guinney J (2013) GSVA:gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform 14:7

Herve P, Marc C, Seth F, Nianhua L (2018) AnnotationDbi:annotation database interface.

Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995-2004

Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet J-P, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385-7392

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550-1558

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG:new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353-D361

Khemlina G, Ikeda S, Kurzrock R (2017) The biology of Hepatocellular carcinoma:implications for genomic and immune therapies. Mol Cancer 16:149

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G (2016) Hepatocellular carcinoma. Nat Rev Dis, Prim, p2

Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15:599-616

Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Shen H (2017) BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling. Mol Carcinog 56:2279-2289

Marc C (2018) org.Hs.eg.db:genome wide annotation for Human.

Mojic M, Takeda K, Hayakawa Y (2017) The dark side of IFNgamma:its role in promoting cancer immunoevasion. Int J Mol, Sci, p19

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453

Ocker M (2018) Biomarkers for hepatocellular carcinoma:what's new on the horizon? World J Gastroenterol 24:3974-3979

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ (2017) Wnt/beta-catenin pathway:modulating anticancer immune response. J Hematol Oncol 10:101

Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L (2016) Resistance mechanisms to immune-checkpoint blockade in cancer:tumor-intrinsic and -extrinsic factors. Immunity 44:1255-1269

Quail DF, Zhang G, Findlay SD, Hess DA, Postovit L-M (2014) Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. Oncogene 33:461-473

R Core Team (2017) R:a language and environment for statistical computing. R Foundation for Statistical Computing. https://www.r-project.org/

Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38:500-501

Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19:368-375

Rengarajan J, Szabo SJ, Glimcher LH (2000) Transcriptional regulation of Th1/Th2 polarization. Immunol Today 21:479-483

Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, Kreutz M (2017) Metabolic hallmarks of tumor and immune cells in the TumorMicroenvironment. Front Immunol 8:248

Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M (2018) The immunology of hepatocellular carcinoma. Nat Immunol 19:222-232. https://doi.org/10.1038/s41590-018-0044-z

Robinson MW, Harmon C, O'Farrelly C (2016) Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 13:267-276

Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D (2010) Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50:1-14

Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy:from enhancement to normalization. Cell 175:313-326

Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud A-L, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc J-F, Mazzaferro V, Calvo F, Villanueva A, Nault J-C, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47:505-511

Sica A, Invernizzi P, Mantovani A (2014) Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 59:2034-2042

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis:a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550

Wakiyama H, Masuda T, Motomura Y, Hu Q, Tobo T, Eguchi H, Sakamoto K, Hirakawa M, Honda H, Mimori K (2018) Cytolytic activity (CYT) score is a prognostic biomarker reflecting host immune status in hepatocellular carcinoma(HCC). Anticancer Res 38:6631-6638

Wang J, Vasaikar S, Shi Z, Greer M, Zhang B (2017) WebGestalt 2017:a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45:W130-W137

Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet J-P, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6:760-769

Zeng S, Zhang Y, Ma J, Deng G, Qu Y, Guo C, Han Y, Yin L, Cai C, Li Y, Wang G, Bonkovsky HL, Shen H (2017) BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2. Cancer Lett 390:67-76

Zhang X, Weng W, Xu W, Wang Y, Yu W, Tang X, Ma L, Pan Q, Wang J, Sun F (2014) Prognostic significance of interleukin 17 in cancer:a meta-analysis. Int J Clin Exp Med 7:3258-3269

Zhang Q, Lou Y, Bai X-L, Liang T-B (2018) Immunometabolism:a novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol 24:3500-3512

Supplements(0)

Relative Articles

Cited By

Proportional views